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Abstract 
Sphingolipids are fundamental to membrane trafficking, apoptosis and cell differentiation and proliferation. KDSR or 3-keto-
dihydrosphingosine reductase is an essential enzyme for de novo sphingolipid synthesis, and pathogenic mutations in KDSR result 
in the severe skin disorder erythrokeratodermia variabilis et progressiva-4. Four of the eight reported cases also had 
thrombocytopenia but the underlying mechanism has remained unexplored. Here we expand upon the phenotypic spectrum of 
KDSR deficiency with studies in two siblings with novel compound heterozygous variants associated with thrombocytopenia, 
anemia and minimal skin involvement. We report a novel phenotype of progressive juvenile myelofibrosis in the propositus, with 
spontaneous recovery of anemia and thrombocytopenia in the first decade of life. Examination of bone marrow biopsies showed 
megakaryocyte (MK) hyperproliferation and dysplasia. MK obtained by culture of CD34+ stem cells confirmed hyperproliferation 
and showed reduced proplatelet formation. The effect of KDSR insufficiency on the sphingolipid profile was unknown, and was 
explored in vivo and in vitro by a broad metabolomics screen that indicated activation of an in vivo compensatory pathway that 
leads to normalisation of downstream metabolites such as ceramide. Differentiation of propositus-derived induced pluripotent 
stem cells to MK followed by expression of functional KDSR showed correction of the aberrant cellular and biochemical 
phenotypes, corroborating the critical role of KDSR in proplatelet formation. Finally, Kdsr depletion in zebrafish recapitulated the 
thrombocytopenia and showed biochemical changes similar to those observed in the affected siblings. These studies support an 
important role for sphingolipids as regulators of cytoskeletal organisation during megakaryopoiesis and proplatelet formation. 
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Introduction 
KDSR or 3-keto-dihydrosphingosine reductase is an early, essential enzyme in the pathway of de novo sphingolipid synthesis that 
catalyzes the conversion of 3-keto-dihydrosphingosine (KDS) to dihydrosphingosine (DHS) on the cytosolic leaflet of the 
endoplasmic reticulum.1 The canonical transcript for KDSR encodes a 332 amino acid protein. The gene is widely transcribed,1-3 
consistent with the integral roles of the sphingolipid family in forming lipid rafts that facilitate membrane trafficking and in the 
regulation of fundamental cellular functions that include apoptosis, differentiation, and proliferation.4 The importance of 
sphingolipid synthesis for normal cellular functions is illustrated by the complex multisystem phenotypes of null mice for key 
enzymes or receptors in the pathway, including defective platelet activation and thrombus formation.5, 6 A pathway for de novo 
synthesis of sphingolipids in a megakaryocytic cell line has been shown, but plays a minimal role in mature platelets, which 
instead acquire essential sphingolipids by incorporating them from plasma or recycling plasma membrane sphingomyelins, both 
largely independently of KDSR.7  
Consistent with these important roles of sphingolipids, compound heterozygous variants in KDSR (Figure 1) have recently been 
identified as causal of the severe skin disorder erythrokeratodermia variabilis et progressiva 4 (EKVP4, OMIM617526), a 
condition characterised by neonatal onset of thick, scaly skin on the face and genitals and milder erythematous palmo-plantar 
scaling.8 This observation established a role for KDSR in the homeostasis of keratinisation, however it was unclear whether these 
cases had hematological pathologies. A more recent study described four probands with EKVP4 caused by KDSR variants 
accompanied by severe thrombocytopenia and platelet dysfunction in infancy.9 A reduction in plasma S1P and surface-exposed 
ceramide in human platelets, as well as diminished ceramide levels in affected skin were reported. Bone marrow morphology in 
one patient was normal and in a second one demonstrated increased megakaryopoiesis. For this patient a diagnosis of immune-
mediated thrombocytopenia was made with no response to corticosteroid treatment and minimal response to splenectomy. No 
further exploration of the molecular mechanism underlying the thrombocytopenia was undertaken.9  
Here we provide evidence that in this pedigree, KDSR plays a fundamental role in megakaryopoiesis, cytoplasmic organisation 
and proplatelet formation. We describe a pedigree in which compound heterozygous variants in KDSR segregate with severe 
thrombocytopenia and minimal or no skin involvement. We report novel phenotypes of progressive juvenile myelofibrosis in the 
propositus, who is older, and anemia in both siblings. Broad metabolic profiling complemented by targeted mass spectrometry 
assays confirm KDSR hypofunction and suggest activation of an alternative, compensatory pathway in vivo. Depletion of kdsr in 
zebrafish and studies with CD34+ stem cell- and induced pluripotent stem cell (iPSC)-derived MK show cellular and biochemical 
signatures in common with those observed in our patients, showing the mechanism by which KDSR variants mediate 
thrombocytopenia. 
 
Methods 
Recruitment and sequencing 
Following informed, written consent (ethical study approval ML3580), the propositus was recruited to the Bleeding, thrombotic 
and Platelet Disorders (BPD) domain of the NIHR BioResource-Rare Diseases study (UK Research Ethics Committee 
13/EE/0325, https://bioresource.nihr.ac.uk). Further details are provided in the supplemental Methods.  
Platelet studies 
Aggregation and electron microscopy (EM) studies were performed as described previously.10  
Metabolic profiling 
Global metabolic profiling of plasma was performed by Metabolon, Inc. (Durham, NC) using the DiscoveryHD4 liquid 
chromatography tandem mass spectrometry (LC-MS/MS) platform, as previously described.11 Results of study participants were 
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compared with 496 subjects between the ages of 4 and 55 years without thrombocytopenia. A separate LC-MS platform method, 
previously described,12, 13 was used for specific confirmation of the global sphingolipid profile. Further details are provided in the 
supplemental Methods.  
Stem cell differentiation assays 
CD34+ hematopoietic stem cells (HSC) were isolated by magnetic cell sorting (Miltenyi Biotec, Bergisch Gladback, DE) from 
bone marrow aspirates from the propositus (at 5 years of age) and an unrelated control, and from peripheral blood from the 
propositus (at 8∙5 years of age), his affected sister (at 5 months of age) and an unrelated control.  
In addition, expanded bone marrow- and peripheral blood- derived HSC at day 3 of differentiation were used for liquid MK 
cultures in two experiments. In the first experiment, HSC obtained from the bone marrow of the propositus were differentiated in 
parallel to a control. For the second experiment, HSC obtained from the peripheral blood of the propositus and his affected sister 
were cultured in parallel with a different control. Details of the differentiation protocols, colony assays and statistical analysis of 
MK immunostaining are provided in the supplemental Methods.  
Zebrafish analysis 
Tg(cd41:EGF) embryos14 were injected at the one-cell stage with a kdsr ATG morpholino (MO) (5’ ctcagaggacatgggtcaacctgat, 
Kdsr-MO) purchased from Gene Tools LLC (Philomath, OR) or with buffer (control). Zebrafish kdsr has ZFIN accession number 
ZDB-GENE-040426-853. Thrombocyte formation was analysed as described previously.15, 16 Immunoblots were developed with 
goat anti-GFP (Rockland) and anti-FVT1/KDSR (Clone H-149; Santa Cruz). All animal protocols were approved by the Ethical 
Committee of KU Leuven. 
Lentiviral reference KDSR transcript expression in iPSC 
iPSC were prepared by the Cambridge Biomedical Research Centre iPSC core laboratory as described in the supplemental 
Methods. iPSC were transduced with the lentiviral vector to express the open reading frame (ORF) of KDSR (pLenti-EF1a-
KDSR-myc-DDK-IRES-Puro, Origene) and the un-cloned destination vector PS10085 (Origene) to generate the reference 
transcript rescue line (Kresc) and empty vector control line (Kev), respectively. The ORF is identical to transcript 
ENST00000591902 (RefSeq accession no. NM_002035, Origene TrueClone cDNA cat. RC201153), which has the highest 
reported expression in MK.2 Details of lentiviral particle production, transduction and selection are given in the supplemental 
Methods.  
Forward programming to MK (iMK) 
iPSC were reprogrammed to MK (named iMK hereafter) using a protocol for generating MK described by Moreau et al.17 Kresc 
and Kev iMK were generated in three independent experiments. Details of iMK reprogramming, immunophenotyping, the 
proplatelet assay and RNA sequencing are given in the supplemental Methods.  
Results 
Clinical characteristics 
The eight-year old male propositus was born to healthy, unrelated parents of European ancestry (Figure 2A). At 4 months of age 
he presented with a viral infection and was found to have a platelet count of 65x109/L and mild normocytic, normochromic 
anemia with normal iron and hematinic levels (Figure 2B, supplemental Table 1A, supplemental Figure 1). Subsequent complete 
blood counts showed on several occasions platelet counts <100x109/L accompanied by rectal and gingival bleeding, excessive 
ecchymosis, and recurrent epistaxis when platelet counts were <10x109/L. Possible skin involvement was limited to a slow-to-heal 
perianal wound following rectal manometry. Serial bone marrow examinations revealed increased numbers of dysplastic MK and 
progressive severe myelofibrosis (Figure 2C, supplemental Figure 2, supplemental Table 1B); despite this we observed significant 
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fluctuation in the propositus’ thrombocytopenia and normalisation of the hemoglobin level over the course of his first decade 
(Figure 2B, supplemental Table 1A). The mechanism of the improvement is unclear, and occurred in the absence of identifiable 
environmental, therapeutic, or dietary interventions. Genetic analyses of bone marrow DNA excluded known somatic mutations 
causal of myelodysplasia or primary myelofibrosis (supplemental Table 1B). Light transmission platelet aggregation was normal 
with the exception of an attenuated response to stimulation with collagen at low dose (supplemental Table 1C). The propositus’ 
older brother and his parents were unaffected (Figure 2A). His sister presented at birth with thrombocytopenia (Figure 2A and B, 
supplemental Table 1A) and mild ichthyosis in her left axilla (Figure 2D), but the skin symptoms resolved spontaneously over the 
first month. At 5 months of age she also developed persistent, normocytic, normochromic anemia (Figure 2B, supplemental Table 
1A). EM analysis showed platelets of normal size without marked ultrastructural differences between patients and controls (Figure 
2E).  
Pathogenic variants in KDSR 
The propositus and his affected sister carry a maternally inherited nonsense variant 18:61006104 G>A (p.Arg236*) and a 
paternally inherited missense variant 18:61018270 G>A (p.Arg154Trp) in KDSR (Figure 2A). The variants were confirmed by 
Sanger sequencing (supplemental Figure 3) and have minor allele frequencies in Europeans of 4∙82x10-5 and 2∙32x10-4 
respectively.18, 19 The missense variant p.Arg154Trp is localised in the catalytic domain of KDSR (Figure 1)20 and both are found 
in the most abundant KDSR transcripts in MK (supplemental Figure 4).2 The nonsense variant is absent from two out of three 
major platelet transcripts, which is in keeping with minimal de novo sphingolipid synthesis in mature platelets (supplemental 
Figure 4).7 The results of co-segregation study were concordant with an autosomal recessive mode of inheritance (Figure 2A). 
Sphingolipid profiles 
We reasoned that the variants would cause reduced enzymatic function, leading to a build-up of the substrate KDS (Figure 3A). 
Indeed global metabolic profiling showed KDS to be detectable in plasma from the propositus while it was undetectable in the 
plasma of the parents, the healthy sibling, and 496 unrelated controls (Figure 3B). This finding was corroborated using a LC-MS 
platform for the selective measurement of specific sphingolipids, which confirmed that KDS was detectable in both patients and 
absent from the plasma of controls (Figure 3C, supplemental Figure 5). Interestingly, there was no reduction in downstream 
sphingolipids in the patients using either platform (supplemental Tables 2 and 3A). In fact, global profiling showed levels of the 
KDSR product, DHS, were higher for the propositus than controls. These findings raise the hypothesis that KDSR hypofunction 
during de novo sphingolipid synthesis is compensated in vivo by alternative mechanisms, for example by the recycling of 
relatively abundant sphingomyelins along a pathway that normally contributes little to free DHS production.4  
Depletion of kdsr in zebrafish causes thrombocytopenia 
We explored the role of the enzyme on thrombocyte formation in zebrafish by MO-mediated depletion of the kdsr transcript in 
Tg(cd41:EGFP). This led as expected to a reduction of the Kdsr protein level  (Figure 4A and B) and resulted in curved tails, 
which is a typical feature for embryos with thrombocytopenia (supplemental Figure 6).15 The number of thrombocytes was 
inversely correlated with the dose of MO injected (Figure 4C and D). Targeted sphingolipid profiling showed elevated and 
undetectable KDS in lysates from MO and control embryos, respectively (Figure 4E). Similar to the results obtained with the 
propositus’ plasma, dihydroceramides, ceramides, sphingomyelins and glycosphingolipids that are downstream of Kdsr were not 
significantly different between Kdsr-depleted and control fish (supplemental Table 3B).  
Impaired proplatelet formation in MK from patients 
CFU-GEMM cultures differentiated from bone marrow HSC of the propositus showed hyperproliferation of myeloid cells 
(p=0∙001, t-test) with a reduced myeloid/erythroid ratio compared to the controls (supplemental Figure 7). CFU-MK numbers 
were comparable to those of the control, although individual MK colonies were denser for the propositus and liquid cultures 
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showed an increased number of MK (supplemental Figure 8). MK in control cultures formed proplatelets, whilst MK derived from 
both the propositus and affected sister showed a strong reduction in proplatelet formation, despite similar levels of membrane 
budding and a higher number of CD41 and CD42 positive cells in propositus-derived cultures when compared with control MK 
(Figure 5A; supplemental Figure 8, 9, and 10). Patient-derived MK also showed extensive, abnormal formation of lamellipodia 
and reduced cell size (p=0∙014, likelihood ratio test, Figures 5B and C).  
The abnormal morphological, functional, and biochemical features of the propositus’ iMK can be rescued   
To corroborate the atypical phenotypes of MK derived from the HSC, we transduced iPSC from the propositus with lentiviral 
vectors containing the reference KDSR ORF (Kresc) or an inert control vector (Kev), and reprogrammed these cells to iMK 
(supplemental Figure 11A). Analysis of the iMK RNA-seq results showed similar KDSR gene expression but the majority of 
sequencing reads in the rescued iMK carried the reference allele at Chr18:61018270 G>A (p.Arg154Trp, supplemental Figures 
11B, C and D). These findings are consistent with correction of the genetic defect without significant overexpression, and resulted 
in increased proplatelet formation compared with control iMK four hours after seeding (Figures 6A, B and C; p=0∙047, t-test). The 
observed iMK proplatelets were shorter and less branched than those observed following directed differentiation from stem cell 
cells, in keeping with published reports using this protocol.17 Upon microscopic inspection the rescued iMK seemed larger than 
the non-rescued ones (which was confirmed to be significant by flow cytometry, supplemental Figure 11E) and the increased 
proplatelet formation resulted by 24 hours in little residual cytoplasm for the rescued versus the non-rescued iMK (Figure 6C). At 
the biochemical level the rescue resulted in a significant reduction of KDS levels (p=0∙02, t-test) showing the effectiveness of the 
gene therapy approach in ‘curing’ the iMK from the propositus (Figure 6D). Similar to findings in plasma and in zebrafish, DHS 
levels did not differ between the iMK with and without functional KDSR transcripts, indicating that the postulated, compensatory 
mechanism is also present in iMK. We searched the iMK transcriptome landscape for possible differences in the levels of 
transcripts of other key enzymes that regulate sphingolipid synthesis and recycling (the enzymes examined are as shown in Figure 
3A). This identified only ASAH1 and CERS6 transcripts to be down- and up- regulated respectively (posterior probabilities 0∙610 
and 0∙774; log fold change -0∙67 and +0∙70, respectively). These two enzymes regulate the ceramide-sphingosine ratio (Figure 3A, 
supplemental Figure 12) and in keeping with these findings, the rescued iMK showed higher sphingosine and lower ceramide 
levels (Figure 6D).  
Discussion 
Pathogenic mutations in KDSR have recently been associated with a recessively inherited syndrome of moderate-to-severe skin 
pathology and thrombocytopenia.8, 9 We have described two novel KDSR mutations causing thrombocytopenia in the propositus 
and his infant sister, expanding the phenotypic spectrum of this recently identified Mendelian disorder from severe skin pathology 
with no apparent hematological involvement to profound thrombocytopenia and moderate anemia with spontaneous improvement 
across the first decade, and almost imperceptible dermatological abnormalities. In the propositus bone marrow studies also 
showed the novel phenotype of severe juvenile myelofibrosis, however the sister was too young to allow confirmation of this 
phenotype. The biochemical sphingolipid signatures of the plasma and patient-derived iMK confirmed the predicted reduction in 
function with elevated levels of its substrate, KDS. This is as expected, from the combination of a variant encoding a premature 
stop codon and a hypomorphic allele involving a missense variant in the catalytic domain. Unexpectedly, downstream metabolites 
in the sphingolipid pathway including DHS, ceramide, and sphingosine-1-phosphate were not reduced in plasma, suggesting that 
KDSR hypofunction during de novo sphingolipid synthesis is compensated by an alternative pathway. One possible alternative 
pathway is the recycling of relatively abundant sphingomyelins, a pathway previously shown to contribute to production of 
downstream sphingolipids such as dihydroceramide, ceramide, and sphingosine, but considered to contribute little, if at all to DHS 
production under normal conditions.21 Post-translational modifications to sphingolipid enzymes may also explain the metabolic 
profile, and further work is required to explore this possibility. Importantly, the profile of increased ceramide and reduced 
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sphingosine in propositus-derived iMK compared with rescued iMK, and the consistent and potentially explanatory transcriptional 
dysregulation of enzymes ASAH1 and CERS6, is at odds with the limited sphingolipid quantitation undertaken in previous studies 
which showed that ceramide levels were reduced in affected skin and that platelet surface exposure of ceramide was impaired in 
individuals with hypo-functional KDSR variants.9  
Our observation that MK lacking functional KDSR are hyperproliferative is consistent with earlier reports,9 but we expand on this 
characterisation by showing the ex-vivo generated patient MK to be smaller than controls and to be less effective in proplatelet 
formation. Proplatelets are pseudopodial projections of megakaryocyte cytoplasm, supported at their core by microtubular bundles 
that carry granules and other platelet cargo from the body of the megakaryocyte to the tip of the proplatelet.22 Aberrant size and 
proplatelet formation were not only observed in MK obtained by differentiation of primary HSC obtained from the two patients, 
but are also present in iMK generated by forward programming of iPSC derived from the propositus’ fibroblasts. All together we 
consider the ineffective platelet formation caused by the absence of KDSR to be the primary cause of the thrombocytopenia. 
Increased turn-over because of a reduced platelet lifespan seems to be a less likely explanation because the immature platelet 
fraction was not significantly raised in the two patients compared with healthy controls (data not shown). We hypothesize that 
impaired platelet formation may, in turn, be caused by cytoskeletal disorganisation and further experiments are required to explore 
this possibility. Pathogenic mutations in several other genes (e.g. MYH9, ACTN1, FLNA, TUBB1, DIAPH1, TPM4) encoding 
proteins with important functional roles in cytoskeletal reorganisation and actin polymerisation are causal of dominant forms of 
thrombocytopenia.23 However these genetic disorders are characterised by enlarged platelets, and the mean volumes of the 
platelets of our patients are within the normal ranges for males and females, respectively.  
The increased level of KDS in plasma was confirmed at the cellular level in iMK derived from the propositus. This increased level 
was normalised upon rescue of the propositus’ iMK with a KDSR transcript carrying the reference allele. The correction of the 
biochemical defect was mirrored by a recovery of iMK size and improvement of their capacity to form proplatelets.  In further 
support of the central importance of KDSR in thrombopoiesis we show that KDSR knockdown in a zebrafish model is associated 
with impaired thrombocyte formation. Similar approaches have identified multiple potential regulators of thrombopoiesis,24 
though in isolation zebrafish studies are limited by inherent differences in thrombopoiesis between mammals and fish, notably that 
zebrafish have nucleate thrombocytes rather than MK. 
The marked, spontaneous improvement of the propositus’ thrombocytopenia and anemia led to reversal of the decision to treat the 
condition by HSC transplantation. The mechanism of this improvement is unclear, given the presence of progressive 
myelofibrosis and in the absence of clinical features to suggest significant extramedullary hemopoiesis such as splenomegaly. 
Recent studies have shown spontaneous improvement in blood counts in other inherited juvenile bone marrow failure syndromes, 
most notably those associated with pathogenic variants in SAMD9 or SAMD9L.25 In these cases the improvement was attributed to 
the acquisition of corrective somatic mutations. Further longitudinal studies of individuals affected by pathogenic KDSR variants 
is essential to determine whether the clinical course described is representative, and whether a careful watch-and-wait approach 
rather than early intervention may be more appropriate in this genetically-defined subgroup of cases with inherited 
thrombocytopenia accompanied by bone marrow failure.  
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Figure 1. Reported KDSR variant genotypes and phenotypes in the context of KDSR structure and function 
Protein and cDNA schematic adapted from Gupta et al20 demonstrating location of known pathogenic KDSR variants with documented 
phenotypes in skin only (black), skin and platelets (red) and the novel variants reported in this manuscript in bold and underlined. Variants are 
linked by brackets where present in compound heterozygosity in an individual. Key structural elements of KDSR are illustrated: transmembrane 
anchors (blue, purple), the Rossman folds (red), and a highly conserved domain containing three putative catalytic sites (yellow). The novel 
p.Arg154Trp variant is within the catalytic domain. 
 
Figure 2. Clinical characteristics associated with loss-of-function KDSR variants 
(A) Pedigree and variants identified in KDSR. ‘+’ denotes the major allele. The propositus and affected sibling, 
but not the healthy sibling, carry the missense variant 18:61018270 G>A (p.Arg154Trp) and the nonsense variant 18:61006104 G>A 
(p.Arg236*). Co-segregation analysis demonstrated that the father carries the former and the mother the latter variant. (B) Serial blood counts 
are shown for the two affected siblings and a single value for the healthy brother. Fluctuating anemia and thrombocytopenia was observed, 
without evidence of neutropenia. (C) Bone marrow biopsy. Left: Numerous dysplastic megakaryocytes made visible with LAT staining are 
present. Right: Marrow fibrosis with strong stromal reticulin staining. Magnification x40. Further images can be found in the supplemental 
materials. (D) The affected sibling was born during the course of this study and presented at birth with thrombocytopenia and mild ichthyosis in 
her left axilla. The skin symptoms improved spontaneously over the first month. (E) Platelets were examined by electron microscopy for an 
unrelated healthy control, the propositus, and the affected sibling. There were no marked morphological differences. Arrowed magnifications 
show δ-granules. Magnification 12,000x.  
 
Figure 3. Metabolic profiling shows that the KDSR variants are associated with loss-of-function and downstream sphingolipid pathway 
compensation  
(A) Simplified sphingolipid pathway highlighting the role of the KDSR enzyme in de novo synthesis (black arrows) and the generation of 
sphingolipid intermediates from the recycling of complex sphingolipids and sphingomyelins (green arrows). (B) Mass spectrometry using the 
Metabolon platform shows the major chromatographic peak of 3-keto-dihydrosphingosine (KDS) in the plasma of the propositus, but not of the 
unaffected pedigree members (shown) or the controls (not shown). (C) KDSR hypofunction was confirmed in the propositus and affected sister 
using a second mass spectrometry platform for targeted sphingolipid profiling. The chromatogram shows that KDS was detected in the plasma 
from the propositus and his affected sister but not in the plasma from the healthy brother, parents (shown), and two controls (not shown).  
 
Figure 4. Kdsr morpholino knockdown is associated with reduced thrombopoiesis in zebrafish 
(A) Tg(cd41:EGF) embryos were injected with a kdsr ATG-MO (1000 µM) or with buffer (control). Embryos were lysed 72 hpf and used for 
immunoblotting. GFP and Kdsr proteins were reduced in the kdsr knockdown condition. Equal amounts (50 μg) were loaded (5 randomly 
selected embryos for each of the 4 conditions). Staining of Gapdh was used as loading control. (B) Quantification of immunoblot after 
normalization for Gapdh. Mean values are plotted and error bars show the standard deviation, analysed by one-way ANOVA. (C) Quantification 
by flow cytometry of the number of GFP-labelled thrombocytes in Tg(cd41:EGFP) Danio rerio embryos at 72 hpf for kdsr-MO (800 or 1000 
µM) or buffer (control) injected fish. Values are means and standard deviations (SD) as quantified for 10 randomly selected embryos for each 
condition, performed in triplicate. Results were analyzed by one-way ANOVA. (D) Greyscale stereo-microscope images (20x original 
magnification) in the tail region at 72 hpf showed a reduced number of GFP-labelled thrombocytes (in white). (E) KDS levels in lysates from 72 
hpf embryos (20/condition) for kdsr-MO (800 µM) or buffer (control) injected fish. KDS was detected in the lysates from the MO-injected 
embryos but not in the control-injected embryos.  
 
Figure 5. KDSR variants are associated with reduced proplatelet formation by megakaryocytes (MK)  
(A) Quantification of proplatelet formation by MK at day 11 of differentiation. On the left are the results of differentiation of bone marrow-
derived hematopoietic stem cells (HSC) from the propositus and control. On the right are the results of differentiation of HSC obtained from the 
blood of the propositus, his affected sibling and a second control. All MK with proplatelets and membrane budding were counted as positive. 
Values plotted are means and standard deviations (SD) as quantified on 20 images. Results were analyzed by the unpaired, two-tailed t-test. (B)  
MK at day 11 derived from bone marrow HSC from the propositus and a control. MK are stained for the cytoskeletal marker F-actin (red) and 
lysosome and δ-granule marker CD63 (green). MK from the propositus and affected sibling have irregular cytoskeletal structures with 
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lamellipodia (arrows). Further images can be found in supplemental Figure 10. (C) MK area was quantified by automated analysis. Modelling 
was performed using a linear mixed effects model and associated p-values were computed by a likelihood ratio test. MK from affected cases 
were smaller compared to unrelated controls (p=0∙01473).  
 
Figure 6. KDSR reference allele expression rescues ineffective proplatelet formation 
Proplatelet formation by iMK. 100% of live MK plated for the proplatelet assay were CD41 positive and 75% were dual positive for CD41 and 
CD42 by flow cytometry (supplemental Figure 11A). Cytoskeletal marker α-tubulin was stained with antibodies in green and nuclei were stained 
with DAPI in blue. Proplatelet formation was counted manually. Values shown were analyzed using the paired, two-tailed Student’s t-test, using 
p<0∙05 for significance and are plotted as means and standard deviations. (A) The number of proplatelets formed at 4 hours per proplatelet-
forming MK (PPFMK) by the rescued and non-rescued iMK. The differences were significant at 4 hours (p=0∙047) but not anymore at 24 hours 
(p=0∙20). (B) The number of PPFMK at 4 hours did not differ significantly between the two groups (7∙1% vs 42∙4% , p=0∙10), but at 24 hours 
the rescued showed less PPFMK (p=0∙03). (C) Representative images from the proplatelet formation assay at 4 and 24 hours. Proplatelets are 
indicated by white arrows. Top left and right panel: Results at 4 hours for rescued iMK show increased proplatelet formation. White scale bars 
indicate 10µm. Bottom left and right panel: Results at 24 hours show little proplatelet formation for the rescued iMK, and residual cells are 
either fragmented into platelet-like particles, or consist of bare nuclei. (D) Metabolon mass spectrometry results for non-rescued and rescued 
iMK. The ion counts for KDS detection differed significantly between the non-rescued and non-rescued iMK (p=0∙02). The DHS level did not 
differ between the groups of samples but the levels of sphingosine and ceramide were lower and higher in the non-rescued versus rescued iMK, 
respectively. 
